avoparcin and Staphylococcal-Infections

avoparcin has been researched along with Staphylococcal-Infections* in 1 studies

Other Studies

1 other study(ies) available for avoparcin and Staphylococcal-Infections

Article	Year
Helvecardins A and B, novel glycopeptide antibiotics. III. Biological properties. The Journal of antibiotics, 1991, Volume: 44, Issue:3 Helvecardins (HVCs) A and B were strongly active against aerobic and anaerobic Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA), but they were inactive against Gram-negative bacteria and fungi. Though HVC A showed only slightly stronger antimicrobial activity than beta-avoparcin (AVP), its in vivo protective activity against S. aureus infection in mice was greatly superior to AVP. Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Female; Glycopeptides; Gram-Positive Bacteria; Lethal Dose 50; Methicillin Resistance; Mice; Staphylococcal Infections; Staphylococcus aureus; Vancomycin	1991

Article

Year

Helvecardins A and B, novel glycopeptide antibiotics. III. Biological properties.

The Journal of antibiotics, 1991, Volume: 44, Issue:3

Helvecardins (HVCs) A and B were strongly active against aerobic and anaerobic Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA), but they were inactive against Gram-negative bacteria and fungi. Though HVC A showed only slightly stronger antimicrobial activity than beta-avoparcin (AVP), its in vivo protective activity against S. aureus infection in mice was greatly superior to AVP.

Topics: Aminoglycosides; Animals; Anti-Bacterial Agents; Female; Glycopeptides; Gram-Positive Bacteria; Lethal Dose 50; Methicillin Resistance; Mice; Staphylococcal Infections; Staphylococcus aureus; Vancomycin

1991